发明名称 FcRn-based therapeutics for the treatment of auto-immune disorders
摘要 Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous FcRn disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a substantially shorter half-life, as compared to the half-life of exogenously administered IgG1 in a wild-type mouse. The transgenic knockout mouse with a homozygous FcRn disruption is also unable to absorb maternal IgG in the prenatal or neonatal stage of development. Also disclosed is a transgenic knockout mouse comprising a homozygous FcRn disruption and a human FcRn transgenic. The transgenic addition of human FcRn results in a substantial increase in the half-life of exogenously administered human IgG1. Methods of using the transgenic knockout mouse, and cells derived from them, are also disclosed.
申请公布号 US6992234(B2) 申请公布日期 2006.01.31
申请号 US20010993322 申请日期 2001.11.06
申请人 THE JACKSON LABORATORY 发明人 ROOPENIAN DERRY
分类号 C07K14/735;C12N15/85 主分类号 C07K14/735
代理机构 代理人
主权项
地址